title: Development of a double-layer microfluidic chip with flow medium for chemotherapy resistance analysis of lung cancer.
abstract: Integration and miniaturization are main advantages of microchip-based systems. Vertical integration of the multiple operations within a multiple-layer chip is expected to satisfy the urgent demand for high-throughput and large-scale applications. This study aimed at establishing a double-layer chip to integrate the operations including the cell culture, the identification of the protein and the detection of the cell viability onto a platform systematically and supplied with flow fresh medium continuously via a syringe pump to mimic the microenvironment in vivo. With this device, human non-small cell lung cancer cell line (SPCA-1) was cultured well; the expression and the activity of multidrug resistance-associated protein (MRP1) were detected by immunofluorescence assay for the cells pretreated with or without MK-571, a known inhibitor of MRP1; apoptosis percentages were assayed for the cells after being treated by the anticancer drug etoposide (VP-16). The results demonstrated that the function of the MRP1 was inhibited by MK-571, and the percentage of apoptotic for the cells pretreated with MK-571 was higher than that of the control (38.2±2.5% versus 12.3±0.85%, p<0.005). All these indicated that the new device could provide a suitable condition for cell culture and functional analysis in biomedical research, and MK-571 is an effective inhibitor of MRP1 associated with the viability of SPCA-1 cell line treated by VP-16.
authors.affiliation: Graduate School of Dalian Medical University, Dalian, P R China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Meng
authors.forename: Zhongzhou
authors.initials: Z
authors.lastname: He
authors.forename: Lichuan
authors.initials: L
authors.lastname: Zhang
authors.forename: Long
authors.initials: L
authors.lastname: Zhao
authors.forename: Encheng
authors.initials: E
authors.lastname: Li
authors.forename: Qianqian
authors.initials: Q
authors.lastname: Zhang
authors.forename: Xiaolin
authors.initials: X
authors.lastname: Zhang
authors.forename: Dongxia
authors.initials: D
authors.lastname: Yang
authors.forename: Lijuan
authors.initials: L
authors.lastname: Zou
authors.forename: Zhancheng
authors.initials: Z
authors.lastname: Gao
authors.forename: Qi
authors.initials: Q
authors.lastname: Wang
mesh_terms: D000970:Antineoplastic Agents / Q000032:analysis / Q000493:pharmacokinetics / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004317:Doxorubicin / Q000032:analysis / Q000493:pharmacokinetics / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm / Q000187:drug effects* / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004867:Equipment Design; D005047:Etoposide / Q000494:pharmacology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D046210:Microfluidic Analytical Techniques / Q000295:instrumentation / Q000379:methods*; D008856:Microscopy, Fluorescence; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D011422:Propionates / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D020112:Rhodamine 123 / Q000032:analysis / Q000493:pharmacokinetics
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin; D004791:Enzyme Inhibitors; D005047:Etoposide; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D011422:Propionates; D011804:Quinolines; D020112:Rhodamine 123; C059141:verlukast; C421109:multidrug resistance-associated protein 1